Raf Sciot

40.2k total citations · 4 hit papers
555 papers, 24.8k citations indexed

About

Raf Sciot is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Oncology. According to data from OpenAlex, Raf Sciot has authored 555 papers receiving a total of 24.8k indexed citations (citations by other indexed papers that have themselves been cited), including 281 papers in Pulmonary and Respiratory Medicine, 152 papers in Rheumatology and 114 papers in Oncology. Recurrent topics in Raf Sciot's work include Sarcoma Diagnosis and Treatment (229 papers), Gastrointestinal Tumor Research and Treatment (80 papers) and Bone Tumor Diagnosis and Treatments (63 papers). Raf Sciot is often cited by papers focused on Sarcoma Diagnosis and Treatment (229 papers), Gastrointestinal Tumor Research and Treatment (80 papers) and Bone Tumor Diagnosis and Treatments (63 papers). Raf Sciot collaborates with scholars based in Belgium, United States and Netherlands. Raf Sciot's co-authors include Maria Dêbiec‐Rychter, Paola Dal Cin, Valeer Desmet, Peter Van Eyken, Herman Van den Berghe, M. van Glabbeke, Fredrik Mertens, Ivo De Wever, Nils Mandahl and Jaap Verweij and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Raf Sciot

545 papers receiving 24.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

2001 975 citations Raf Sciot et al. profile →
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease

2005 789 citations Raf Sciot et al. profile →
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 654 citations Maria Dêbiec‐Rychter, Raf Sciot et al. profile →
Consensus meeting for the management of gastrointestinal stromal tumors  Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

2005 561 citations Jean‐Yves Blay, Angelo Paolo Dei Tos et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raf Sciot Belgium	81	12.5k	5.7k	5.2k	5.0k	4.6k	555	24.8k
Brian P. Rubin United States	67	11.1k 0.9×	3.7k 0.6×	4.2k 0.8×	7.3k 1.5×	3.6k 0.8×	275	19.2k
Robert G. Maki United States	88	18.3k 1.5×	3.7k 0.6×	9.7k 1.9×	8.0k 1.6×	3.9k 0.9×	377	26.3k
Pancras C.W. Hogendoorn Netherlands	85	15.7k 1.3×	9.5k 1.7×	6.9k 1.3×	2.9k 0.6×	5.1k 1.1×	443	26.7k
Masazumi Tsuneyoshi Japan	74	8.3k 0.7×	3.5k 0.6×	7.6k 1.4×	1.2k 0.2×	6.2k 1.3×	577	22.3k
Raphael E. Pollock United States	74	11.3k 0.9×	3.9k 0.7×	7.9k 1.5×	1.2k 0.2×	2.7k 0.6×	369	18.7k
Yoshinao Oda Japan	64	7.7k 0.6×	2.3k 0.4×	8.7k 1.7×	872 0.2×	6.3k 1.4×	948	20.4k
Silvana Pilotti Italy	68	5.3k 0.4×	2.3k 0.4×	6.6k 1.3×	855 0.2×	5.1k 1.1×	294	16.2k
Masashi Fukayama Japan	78	6.1k 0.5×	1.4k 0.2×	8.3k 1.6×	1.2k 0.2×	8.4k 1.8×	615	24.1k
Claudio Doglioni Italy	83	5.7k 0.5×	1.6k 0.3×	11.6k 2.2×	685 0.1×	8.6k 1.9×	475	26.8k
Gregory Y. Lauwers United States	88	7.2k 0.6×	1.8k 0.3×	11.2k 2.1×	2.4k 0.5×	5.4k 1.2×	448	28.5k

Countries citing papers authored by Raf Sciot

Since Specialization

Citations

This map shows the geographic impact of Raf Sciot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raf Sciot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raf Sciot more than expected).

Fields of papers citing papers by Raf Sciot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raf Sciot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raf Sciot. The network helps show where Raf Sciot may publish in the future.

Co-authorship network of co-authors of Raf Sciot

This figure shows the co-authorship network connecting the top 25 collaborators of Raf Sciot. A scholar is included among the top collaborators of Raf Sciot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raf Sciot. Raf Sciot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vanleeuw, Ulla, Daphne Hompes, Joris Jaekers, et al.. (2025). Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research. Disease Models & Mechanisms. 18(2).

Claerhout, Sofie, Sara Vander Borght, Lien Spans, et al.. (2024). Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours. The Journal of Pathology Clinical Research. 10(3). e12376–e12376. 1 indexed citations

Marcelis, Lukas, et al.. (2024). The Imaging Appearance of EWSR1::PATZ1 Gene Fusion Central Nervous System Tumors. SHILAP Revista de lepidopterología. 108(1). 107–107. 1 indexed citations

Woźniak, Agnieszka, Ulla Vanleeuw, Nina Linde, et al.. (2023). Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST). Clinical Cancer Research. 29(15). 2859–2868. 9 indexed citations

Clément, Paul M., Oliver Bechter, Herlinde Dumez, et al.. (2017). Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma. Sarcoma. 2017. 1–7. 1 indexed citations

Arbajian, Elsa, Florian Puls, Cristina R. Antonescu, et al.. (2017). In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. Clinical Cancer Research. 23(23). 7426–7434. 65 indexed citations

Woźniak, Agnieszka, Piotr Rutkowski, Patrick Schöffski, et al.. (2014). Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research. 20(23). 6105–6116. 121 indexed citations

Jin, Yuesheng, Emely Möller, Karolin H. Nord, et al.. (2012). Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes and Cancer. 51(5). 510–520. 109 indexed citations

Floris, Giuseppe, Agnieszka Woźniak, Raf Sciot, et al.. (2012). A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clinical Cancer Research. 19(3). 620–630. 59 indexed citations

10.

Floris, Giuseppe, Maria Dêbiec‐Rychter, Agnieszka Woźniak, et al.. (2011). The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics. 10(10). 1897–1908. 37 indexed citations

11.

Woźniak, Agnieszka, Piotr Rutkowski, Raf Sciot, et al.. (2010). Genomic profiling discloses differences in imatinib-resistant gastrointestinal stromal tumors (GIST) with primary KIT exon 9 or KIT exon 11 mutations. 1 indexed citations

12.

Floris, Giuseppe, Maria Dêbiec‐Rychter, Raf Sciot, et al.. (2009). Abstract #4692: Efficacy of IPI-504 \#8220;a novel inhibitor of heat shock protein 90\#8221; in a preclinical mouse model of gastrointestinal stromal tumor (GIST). Cancer Research. 69. 4692–4692. 1 indexed citations

13.

Brems, Hilde, Caroline Park, Ophélia Maertens, et al.. (2009). Glomus Tumors in Neurofibromatosis Type 1: Genetic, Functional, and Clinical Evidence of a Novel Association. Cancer Research. 69(18). 7393–7401. 92 indexed citations

14.

Floris, Giuseppe, Maria Dêbiec‐Rychter, Raf Sciot, et al.. (2009). High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. Clinical Cancer Research. 15(12). 4066–4076. 49 indexed citations

15.

Gasparotto, Daniela, Sabrina Rossi, Italo Bearzi, et al.. (2008). Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity. Clinical Cancer Research. 14(18). 5715–5721. 57 indexed citations

16.

Gijselinck, Ilse, Kristel Sleegers, Sebastiaan Engelborghs, et al.. (2007). Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. Ghent University Academic Bibliography (Ghent University). 3 indexed citations

17.

Denys, Hannelore, Olivier De Wever, Betty Nusgens, et al.. (2004). Invasion and MMP expression profile in desmoid tumours. British Journal of Cancer. 90(7). 1443–1449. 42 indexed citations

18.

Wever, Ivo De, Paola Dal Cin, Christopher D.�M. Fletcher, et al.. (2000). Cytogenetic, Clinical, and Morphologic Correlations in 78 Cases of Fibromatosis: A Report from the CHAMP Study Group. Modern Pathology. 13(10). 1080–1085. 56 indexed citations

19.

Delaere, Pierre, et al.. (1995). Experimental tracheal allograft revascularization and transplantation. 3 indexed citations

20.

Sciot, Raf, et al.. (1990). Regulation of ferritin and transferrin receptor expression by iron overload in adult human hepatocytes and a human hepatoblastoma cell line (Hep G2). Hepatology. 12(4). 928. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact